| Literature DB >> 36247094 |
Derek L Nguyen1, Kelly S Myers1, Eniola Oluyemi1, Lisa A Mullen1, Babita Panigrahi1, Joanna Rossi1, Emily B Ambinder1.
Abstract
Unlike mammography and US, limited data exist to establish well-defined criteria for MRI findings that have a ≤2% likelihood of malignancy. Therefore, determining which findings are appropriate for a BI-RADS 3 assessment on MRI remains challenging and variable among breast radiologists. Emerging data suggest that BI-RADS 3 should be limited to baseline MRI examinations (or examinations with less than two years of prior comparisons) performed for high-risk screening and only used for masses with all of the typical morphological and kinetic features suggestive of a fibroadenoma or dominant enhancing T2 hypointense foci that is distinct from background parenchymal enhancement and without suspicious kinetics. This article presents an updated discussion of BI-RADS 3 assessment (probably benign) for breast MRI using current evidence. © Society of Breast Imaging 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: BI-RADS 3; breast MRI; probably benign
Year: 2022 PMID: 36247094 PMCID: PMC9549780 DOI: 10.1093/jbi/wbac032
Source DB: PubMed Journal: J Breast Imaging ISSN: 2631-6110